25 September 2017

IBA Hosts Meeting for Analysts and Investors at ASTRO

 

Louvain-La-Neuve, Belgium, September 25, 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, is today hosting an event for analysts and investors in the Omni San Diego Hotel during the American Society of Radiation Oncology’s (ASTRO) 59th Annual meeting.

 

The event will be hosted by Olivier Legrain, Chief Executive Officer, who will provide an overview of IBA’s business as well as discuss its new collaboration with Elekta. No new material information will be provided.

 

Presentations will also be provided by proton therapy market experts, Dr Andrew K. Lee, Medical Director at the Texas Center for Proton Therapy, Dr Craig Stevens, Chair of Radiation Oncology at the Beaumont Health System and Beth Klein, Executive Vice President at IBA North America.

 

The event will be recorded and the recording as well as the presentation will be available on IBA’s website after the event at: https://iba-worldwide.com/content/iba-capital-market-day-astro-annual-meeting-2017

 

 

Schedule:

 

  • Introduction

Olivier Legrain, Chief Executive Officer, IBA

 

  • The role on proton therapy in oncology

Andrew K. Lee, MD, MPH, Medical Director, Texas Center for Proton Therapy

 

  • Testimony on the development of a state-of-the-art proton therapy center

Craig W. Stevens, MD, PhD, Chair of Radiation Oncology, Beaumont Health System

 

  • North America PT market dynamics

Beth Klein, Executive Vice President at IBA North America.

 

  • Question and answer session with all speakers

 

  • Optional tour of IBA’s booth, # 2135, from 4pm

 

 

 

 

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

 

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com  

 

 

For further information, please contact:

 

IBA

Bernard Dandoy

Investor Relations

+32 10 47 58 90

Investorrelations@iba-group.com

 

Thomas Ralet

Vice-President Corporate Communication

+32 10 47 58 90

communication@iba-group.com

 

For media and investor enquiries:

 

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan

+44 (0) 20 3709 5700

IBA@consilium-comms.com

 

 


Back to previous page